KLOW Blend
Fixed-ratio repair blend with an anti-inflammatory brake · GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg
KLOW is a pre-mixed, single-vial blend of four peptides — 50 mg of the copper tripeptide GHK-Cu, 10 mg of BPC-157, 10 mg of TB-500 (Thymosin β4), and 10 mg of KPV — sold as one 80 mg powder in a fixed 5 : 1 : 1 : 1 ratio. It is GLOW with the KPV added: the same three repair signals plus an anti-inflammatory brake, which is why KLOW is the member of the family positioned for reactive, inflamed, or post-procedure skin rather than for plain remodeling. It is not a new molecule — each peptide keeps its own identity and pharmacology, and the blend simply lets one draw deliver all four in the vial's proportions. The evidence for each component is separate and, for injected use, overwhelmingly preclinical; no published study has tested the four together. None of the four is an approved drug, and BPC-157 and TB-500 are prohibited in sport (WADA).
TL;DRThe whole page · in 30 seconds
Calm + repair · Reactive skin · Post-procedure recovery · Four peptides, one draw
The repair trio with the inflammation dialed down. KLOW packs GHK-Cu's collagen-and-matrix remodeling, BPC-157's blood-supply-building repair, TB-500's repair-cell migration, and KPV's anti-inflammatory brake into a single 80 mg vial — the blend people reach for when the skin or tissue they want to rebuild is also angry.
The basics
- A pre-mixed powder: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV (a 5 : 1 : 1 : 1 ratio). One vial, one draw, all four every time.
- It is [[glow-blend|GLOW]] plus [[kpv|KPV]] — same three repair signals, same per-unit amounts of each, with a calming fourth on top. Wolverine is the stripped-down injury pair.
Why people use it
- Repair that happens in calmer tissue — KPV turns down NF-κB, the master inflammatory switch, inside gut and immune cells.
- Firmer, smoother-looking skin — GHK-Cu switches on collagen, elastin, and the skin's matrix in skin cells.
- Heals wounds and scars with better blood supply — BPC-157 grows new vessels into the repair zone; TB-500 pulls repair cells in.
- One shot instead of four — the whole calm-and-rebuild set in a single daily draw.
How to run it
- Dose: 10 units a day (≈ 2.67 mg of blend = 1.67 mg GHK-Cu + 333 mcg each of BPC-157, TB-500 and KPV); 5 units to start, 15 at the top
- How often: Once daily
- How: A small injection under the skin (belly fat) — one syringe covers all four
- When: Evening — rides your overnight repair window
- Cycle: 4 weeks (one vial at 10 units), then 2–4 weeks off; skin-remodeling runs go 8–12 weeks, then a 4-week break
Stacks well with
- A separate KPV vial — the blend gives you 333 mcg once a day, and an acute flare is run at 400–500 mcg twice daily; a second standalone KPV dose is how people cover that without touching the blend.
- Wolverine Blend or separate BPC-157 + TB-500 vials — when an injury is the real target, the copper-free pair lets you push those two harder without dragging the GHK-Cu load up with them.
Good to know
- The ratio is the trade-off: at 10 units BPC-157, TB-500 and KPV all sit mid-band, but GHK-Cu is already running in its own high tier — past ~12 units the copper peptide runs away from the other three.
- KPV's flare dose is a frequency change, not a bigger dose — 400–500 mcg twice daily. A once-daily blend can't express that, so a flare means a separate KPV vial, not more KLOW.
- A faint blue tint is normal — that's the copper in GHK-Cu. A 10-unit dose carries about 0.26 mg of copper; injected copper skips the gut's usual regulation, so don't add copper supplements on top.
- Banned in tested sport — BPC-157 and TB-500 are both on the WADA list. TB-500 promotes new blood vessels and cell migration, so people with an active or recent cancer avoid it.
- Once mixed, treat the vial like its most fragile member: refrigerate and finish it within about 4 weeks (one vial at 10 units is 30 doses).
Molecular identity
Specs
- Composition
- GHK-Cu 50 mg · BPC-157 10 mg · TB-500 10 mg · KPV 10 mg = 80 mg per vialCross-source vendor agreement
- Ratio
- 5 : 1 : 1 : 1 by mass — 62.5 % GHK-Cu · 12.5 % BPC-157 · 12.5 % TB-500 · 12.5 % KPVCalculated
- Structure / class
- Fixed-ratio, co-lyophilized blend of four research peptides in one vial — not a new molecule; each component keeps its own identity and pharmacology. White to off-white powder with a faint blue tint from the copperCross-source vendor agreement
- GHK-Cu (50 mg)
- Gly-His-Lys · Cu(II) chelate · C14H23CuN6O4+ · 402.92 g/mol · CAS 89030-95-5PubChem CID 71587328
- BPC-157 (10 mg)
- GEPPPGKPADDAGLV (15 AA) · C62H98N16O22 · 1,419.5 g/mol · CAS 137525-51-0PubChem CID 9941957
- TB-500 (10 mg)
- Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (43 AA) · C212H350N56O78S · ~4,963 g/mol · CAS 77591-33-4PubChem CID 16132341 · UniProt P62328
- KPV (10 mg)
- Lys-Pro-Val (3 AA) · C16H30N4O4 · 342.43 g/mol · CAS 67727-97-3PubChem CID 125672
- Copper per vial
- ≈ 7.9 mg elemental copper — GHK-Cu is 15.8 % copper by mass; ≈ 0.26 mg per 10-unit dose (adult oral RDA 0.9 mg/day; oral UL 10 mg/day — not an injected-copper limit)Calculated from PubChem masses
- Half-life (per component)
- No single clock — BPC-157 clears within minutes (rat IV), TB-500 within roughly half an hour to two hours (human IV), GHK-Cu and KPV not established; the blend inherits four separate curves, not onePMID 36588717 · PMID 34346165 · Not established
- Molecular target
- Four separate targets, not one — GHK-Cu carries copper and signals extracellular-matrix synthesis in dermal fibroblasts; BPC-157 acts through the VEGFR2–Akt–eNOS angiogenic pathway; TB-500 sequesters monomeric G-actin; KPV enters cells via PepT1 and inhibits intracellular NF-κB and MAPK signalingPMID 27847966 · UniProt P62328 · PMID 18061177
- Regulatory status
- Not an approved drug in any form; no trial has tested the four-peptide combination; BPC-157 and TB-500 are prohibited in sport (WADA S0 / S2.3)FDA / WADA Prohibited List
Plain English
Mechanism
A blend is a packaging decision, not a new drug. KLOW is one freeze-dried powder that contains four separate peptides, so when you add water you get all four in solution together and every draw carries them in the vial's fixed proportions — 50 parts GHK-Cu to 10 parts each of BPC-157, TB-500, and KPV by weight. Nothing about that changes how each peptide works; it changes only how you measure them. The one chemistry question people raise is whether the copper in GHK-Cu attacks the others in the vial. For BPC-157 the answer is a clean no: copper goes after sulfur-containing amino acids (methionine and cysteine), and BPC-157 — C62H98N16O22 — contains no sulfur at all. The same reasoning clears KPV, whose formula is C16H30N4O4: no sulfur, nothing for copper to attack. TB-500 does carry one methionine, so a slow copper-driven oxidation is at least chemically possible in a stored, reconstituted vial — a theoretical point, since nobody has published stability data on the mixed solution. The practical answer is the same one that applies to every reconstituted vial: keep it cold and use it within about four weeks.
GHK-Cu supplies the remodeling signal, and at 62.5 % of the vial it is what KLOW mostly is by weight. It is a three-amino-acid peptide (glycine–histidine–lysine) carrying a single copper(II) ion, found naturally in human plasma. In cultured human skin fibroblasts — the cells that build connective tissue — it stimulates the synthesis of collagen, elastin, and the other components of the skin's supporting matrix, and the copper it delivers feeds lysyl oxidase, the enzyme that cross-links new collagen and elastin into durable tissue. The honest caveat carries over from its own page: the robust evidence is topical and in-vitro (cells in a dish), most of the foundational reviews come from the molecule's discoverer, and there is no published human trial of injected, systemic GHK-Cu.
BPC-157 supplies the repair-and-blood-supply signal. A 15-amino-acid fragment of a protective gastric protein, it is studied for switching on angiogenesis — the growth of new blood vessels that feed a healing site — through the VEGFR2–Akt–eNOS pathway, and for speeding the migration of fibroblasts by activating their FAK/paxillin traction machinery. TB-500 (the synthetic form of Thymosin β4, the body's main actin-sequestering peptide) supplies the cell-migration signal: by controlling actin, the protein cells use to build their internal scaffolding, it speeds the movement of repair cells — fibroblasts, keratinocytes, blood-vessel-lining cells — into damaged tissue, raises VEGF, and dampens NF-κB-driven inflammation. Both circulate systemically after a subcutaneous injection, so they act on distant tissue, not just around the injection site.
KPV is the component that makes KLOW something other than GLOW, and it is the only one of the four that is not a rebuilder. It is the C-terminal tripeptide of α-melanocyte-stimulating hormone (lysine–proline–valine, residues 11-13), and much of α-MSH's anti-inflammatory activity has long been attributed to that fragment. Its mechanism is intracellular rather than surface-receptor: it is carried into intestinal and immune cells by PepT1, the di/tripeptide transporter, and there inhibits NF-κB and MAP-kinase signaling — two of the cell's master inflammation switches — reducing pro-inflammatory cytokine output. The receptor point matters for how you read it: in colitis experiments KPV still protected mice that lacked a functional MC1 receptor, so its gut effect does not run through the classic melanocortin receptor its parent hormone uses. What it adds to the blend is a fourth kind of lever — a brake, not another accelerator.
Why people combine them is the complementarity: four different levers on one job — the matrix and collagen quality (GHK-Cu), the blood supply and structural rebuild (BPC-157), the arrival of repair cells (TB-500), and the inflammatory tone the whole thing happens in (KPV). Read the evidence level honestly, though: it is four separate, mostly animal and cell-culture evidence bases stacked side by side. No published study has tested GHK-Cu, BPC-157, TB-500, and KPV together, in any model, at any ratio, so the synergy is reasoned from mechanism rather than shown in a trial — and the 50/10/10/10 recipe itself is a market convention, not a studied formulation. Two of the four also carry a route mismatch worth naming: GHK-Cu's human evidence is topical, and KPV's strongest evidence is oral and local to the gut.
Sources:PubChem CID 9941957PubChem CID 16132341PubChem CID 71587328PubChem CID 125672PMID 21780203PMID 8227353PMID 26236730PMID 27847966PMID 21030672PMID 10469335PMID 25313062PMID 34992578PMID 18061177PMID 27458604PMID 18092346PMID 28143741PMID 17934097
Why people reach for it
Potential benefits
KLOW is the blend people reach for when the tissue they want to rebuild is also reactive — inflamed skin, a post-procedure face, a recovery where the inflammation is half the problem. Here's what draws them to it.
- Repair that happens in calmer tissue — The reason KLOW exists rather than GLOW: KPV is carried inside gut and immune cells and turns down NF-κB and MAP-kinase, the switches that drive inflammatory cytokine output, so the three repair signals do their work in a quieter environment — the lever people reach for on reactive or post-procedure skin.
- Firmer, smoother-looking skin — GHK-Cu's headline appeal, carried at 62.5 % of the vial: in cultured skin cells it switches on collagen, elastin, and the matrix that keeps skin firm, and delivers the copper that cross-links new tissue into something durable.
- Scars and wounds that heal with better blood supply — BPC-157 grows new vessels into a repair zone and speeds the cells that rebuild connective tissue, while TB-500 gets repair cells moving into the wound — the pair users lean on for healing that finishes cleaner.
- One draw instead of four — The practical reason the blend exists: one vial, one reconstitution, one daily injection that delivers all four peptides in a fixed ratio — fewer sticks, fewer vials to track, no separate mixing.
- A whole-body signal, not just a local one — TB-500 and BPC-157 circulate after a subcutaneous injection, and KPV is the honest exception — its own evidence is oral and local to the gut, so the whole-body part of its contribution is reasoned from mechanism rather than shown in a study. People use KLOW for tendons, ligaments, gut, and post-procedure recovery well away from the injection site.
- Three of four components inside their own bands — and an honest ceiling — At the community-standard 10 units, BPC-157, TB-500 and KPV all land comfortably inside their own pages' standard ranges (333 mcg each — the lower half of the 250–500 and 300–500 mcg bands — and ≈ 2.3 mg/week for TB-500). GHK-Cu is the one that runs ahead: at 1.67 mg it is already in its own 1.5–2 mg high band, and by 12 units it reaches the 2 mg/day its page tops out at, which is what sets the blend's ceiling.
Sources:PMID 26236730PMID 8227353PMID 27847966PMID 10469335PMID 18061177PMID 34992578
What people reach for KLOW for, drawn from what each component's research reports (predominantly cell-culture and animal work; injected GHK-Cu has no human trial and KPV has none at all) and how the blend is used — no study has tested the four together, and none of this is a proven outcome or a medical claim.
Implied timing
Best time to dose
Implied best time
Evening
Most people inject KLOW in the evening, lining all four signals up with the body's overnight recovery window — the same call the GHK-Cu, BPC-157, and TB-500 pages make, and the mild lean the KPV page allows.
- Overnight is when the body does most of its rebuilding — deep sleep brings the natural growth-hormone pulse, peak tissue regeneration, and the least mechanical load on healing tissue. An evening dose puts GHK-Cu's matrix signal, BPC-157's vessel-growth signal, TB-500's cell-migration signal, and KPV's anti-inflammatory brake to work as that window opens.
- None of the four has a circadian rule of its own: BPC-157 clears the blood in minutes (rat IV) and TB-500 in a few hours (human IV), so the value is in the repair signal each leaves behind; GHK-Cu's remodeling effect is a slow signal rather than a stimulant, and KPV works through a steady anti-inflammatory mechanism with no clock attached. That makes consistency matter more than the exact hour.
- KPV is the one component whose own page calls the timing flexible rather than evening — it lands on "anytime, be consistent," with a mild evening lean for gut and overnight-repair goals. That lean agrees with the other three, so evening is the setting where nothing in the vial is being fought.
- Because the blend is one daily draw, there is no split schedule to juggle — a single consistent evening slot is the whole timing plan. Morning works if evening is impractical; the peptides don't care, the habit does.
No study establishes an ideal time of day for KLOW or for any of its four components — this is reasoned from their mechanisms and how they're used. As a rule of thumb most peptide dosing lands in the midday-to-evening window; for KLOW the lean is evening, to align with overnight repair.
Sources:PMID 36588717PMID 34346165
How to run it
Dosing & protocol
KLOW is dosed here as one subcutaneous injection a day, measured as total blend on a U-100 insulin syringe — the form it's sold in and the route every calculator on this site is built for. The defining fact of a blend is that you dose all four peptides with one number: pick the units and the ratio decides how much of each you get. The tiers below are built from the four component pages' own ranges so you can see, at each draw size, what every peptide is doing relative to its own convention. Read it as a map of how people actually run KLOW — not a validated prescription.
Community convention, not trial-proven: no study has tested the GHK-Cu + BPC-157 + TB-500 + KPV combination, injected GHK-Cu has no human trial, KPV has no human trial at all, TB-500 has no validated systemic human dose (its human trials are IV PK/safety only), and BPC-157's systemic evidence is preclinical. None of the four is FDA-approved. Every number here is a usage pattern assembled from the component pages — not a medical recommendation.
Tiered dose ranges (total blend per draw)
Standard mix: 80 mg vial + 3 mL bacteriostatic water = 26,667 mcg/mL, so 1 unit on a U-100 syringe ≈ 267 mcg of blend (≈ 167 mcg GHK-Cu + 33 mcg each of BPC-157, TB-500, and KPV).
- Low / first week — 5 units (≈ 1.3 mg):
- ≈ 833 mcg GHK-Cu + 167 mcg each of BPC-157, TB-500, and KPV once daily. GHK-Cu sits between its own page's low band (500–750 mcg) and its 1 mg standard; BPC-157 lands inside its 150–250 mcg low band; TB-500 works out to ≈ 1.2 mg/week, inside its light-support band; KPV at 167 mcg is just under the 200 mcg its page calls maintenance. Used to check tolerance, or as a light maintenance dose.
- Standard — 10 units (≈ 2.67 mg):
- ≈ 1.67 mg GHK-Cu + 333 mcg each of BPC-157, TB-500, and KPV once daily — the community convention. Three of the four land comfortably inside their own bands: BPC-157 in the lower half of its 250–500 mcg range, KPV in the lower half of its 300–500 mcg range, and TB-500 at ≈ 2.3 mg/week, inside its 2–2.5 mg once-weekly maintenance band.3 mg/week, which lands inside its 2–2.5 mg once-weekly maintenance band, delivered as seven small daily doses rather than one bolus — an arithmetic equivalence, not a demonstrated one. GHK-Cu is the outlier — 1.67 mg is above the 1 mg its page calls standard and inside its 1.5–2 mg high tier. That is the ratio's honest shape: the copper peptide is already running high when everything else is running normal.
- High / ceiling — 15 units (4 mg):
- ≈ 2.5 mg GHK-Cu + 500 mcg each of BPC-157, TB-500, and KPV once daily. BPC-157 reaches its active-injury dose, KPV the top of its once-daily standard range, and TB-500 ≈ 3.5 mg/week (between maintenance and loading) — but GHK-Cu is now above the 2 mg/day its own page tops out at, with no data showing added benefit past 1 mg. That copper load, not the other three peptides, is why the blend's ceiling sits here. Users who see 20-unit protocols online are running ≈ 3.3 mg GHK-Cu/day; if the goal needs loading-level BPC-157 or TB-500, the honest move is separate vials (or Wolverine) rather than more KLOW.
- What the ratio cannot do — KPV's flare tier:
- KPV's own high tier is not a bigger dose, it is a second one: 400–500 mcg twice daily (≈ 800–1,000 mcg/day), typically held to 7–10 days. A once-daily blend structurally cannot express a frequency change. Chasing it with volume would mean ≈ 30 units of KLOW, which is 5 mg of GHK-Cu a day — two and a half times that peptide's own ceiling. The honest answer is a separate KPV vial alongside the standard KLOW draw, not a bigger draw.
Subcutaneous administration
KLOW is injected into subcutaneous fat; because it's one draw a day, site rotation and a consistent evening slot are the only execution choices.
- Injection site:
- Abdomen (a couple of inches clear of the navel), the love-handle area, or the outer thigh. Rotate sites daily — copper-containing solutions are the ones people most often report a little site irritation from, and rotation is the fix. Injecting near a scar or healing area is a common user preference, not a requirement: BPC-157 and TB-500 circulate systemically.
- Measuring the dose:
- Drawn on a U-100 insulin syringe from the reconstituted vial. At the standard 80 mg + 3 mL mix: 5 units ≈ 1.3 mg · 10 units ≈ 2.67 mg · 15 units = 4 mg of blend. The calculator on this page shows what each draw contains of every component, for any vial size or water volume.
- Time of day:
- Evening — see Best time to dose above. There is no circadian constraint on any of the four, so a consistent daily time matters more than the exact hour; morning is fine if evening doesn't fit.
- Food window:
- Subcutaneous injection; none of the four competes with food for absorption. Inject independent of meals.
Cycle & washout
One vial at the standard draw is a natural 4-week block — the shortest component cycles (BPC-157's 4–6 weeks and KPV's 4–8) set the floor at 4 weeks, and GHK-Cu's 8–12-week remodeling runs set the ceiling, and KPV's 4–8-week pulse sits comfortably inside both.
- Standard block:
- 4 weeks at 10 units/day — one 80 mg vial covers it with a couple of doses to spare (30 doses in the vial, 28 in the block). Then 2–4 weeks off. The most common way KLOW is run, and the cleanest: one vial, one block, reassess.
- Skin-remodeling run:
- 8–12 weeks of continuous daily use (two to three vials) for scar, texture, and post-procedure remodeling goals, mirroring the GHK-Cu page's standard cycle; then a 4-week break. Note that this runs KPV past the 4–8 weeks its own page pulses it for — immune-modulating peptides are conventionally cycled rather than run indefinitely, which is a reason many taper to 5 units for the back half rather than continuing at 10.
- Washout:
- 2–4 weeks off after a 4-week block; 4 weeks after a long run. Reassess the skin or tissue goal during the break — photographs work better than memory for skin — before deciding whether to repeat.
- When a flare or an injury interrupts the block:
- Neither is a reason to raise the blend. For an inflammatory flare, add a standalone KPV dose for 7–10 days. For an acute injury, KLOW is not built for TB-500 loading (that is 2–2.5 mg twice weekly, 4–5 mg/week) — some add one separate 2–2.5 mg TB-500 dose per week on top of 10 units for the first 4–6 weeks; the alternative is to run Wolverine or separate vials for the injury and keep KLOW for the skin goal.
Reconstitution at a glance
The on-page calculator does this live and splits every draw into its four components; the quick reference for the standard 80 mg vial:
- Mixing (3 mL — the common convention):
- 80 mg vial + 3 mL bacteriostatic water = 26,667 mcg per mL (≈ 26.7 mg/mL). On a 100-unit (1 mL) insulin syringe: 5 units ≈ 1,333 mcg · 10 units ≈ 2,666 mcg · 15 units = 4,000 mcg of blend. Each unit ≈ 167 mcg GHK-Cu + 33 mcg each of BPC-157, TB-500, and KPV.
- Mixing (2 mL — the compact alternative):
- 80 mg + 2 mL = 40,000 mcg/mL, so 1 unit ≈ 400 mcg of blend and the standard 2.67 mg dose becomes ≈ 6.7 units. The 3 mL mix simply lands the common dose on a round 10-unit mark; either works — just don't switch water volume mid-vial without redoing the math.
- Why a KLOW unit matches a GLOW unit:
- At the same 3 mL, a KLOW unit delivers exactly the same 167 mcg GHK-Cu + 33 mcg BPC-157 + 33 mcg TB-500 as a GLOW unit and simply adds 33 mcg of KPV — the extra 10 mg of powder is carried by the extra concentration, not by diluting the other three. Anyone switching between the two vials keeps the same unit count.
- Why the split matters more than the total:
- The syringe measures total blend, but each component's safety and dose logic lives on its own page. The calculator's 'this dose contains' readout is the number to compare against those pages. The split assumes the standard 50/10/10/10 recipe; if your label lists a different ratio, this page's arithmetic doesn't apply to it.
- Copper arithmetic:
- GHK-Cu is 15.8 % copper by mass (Cu 63.55 ÷ GHK-Cu 402.92 g/mol), so an 80 mg vial holds ≈ 7.9 mg of elemental copper and a 10-unit dose delivers ≈ 0.26 mg — under a third of the adult oral RDA (0.9 mg/day) and far under the oral upper limit (10 mg/day). The comparison is context only: those limits govern copper eaten and regulated by the gut, and there is no established safety threshold for copper injected past it.
Sources:PMID 8227353PMID 26236730PMID 27847966PMID 36588717PMID 10469335PMID 34346165PMID 18061177PMID 18092346PubChem CID 71587328NIH ODS
Substrate the signal needs
Nutritional cofactor precision
KLOW's four levers are matrix remodeling (GHK-Cu), angiogenesis and structural rebuild (BPC-157), repair-cell migration (TB-500), and the inflammatory brake (KPV). The cofactors follow those levers — supply the collagen the remodeling signal builds with, push the same anti-inflammatory brake KPV is already pushing, and, uniquely for this blend, manage copper the right way round: KLOW already delivers it.
Reasoned from the four components' mechanisms plus general connective-tissue and anti-inflammatory nutrition — not a KLOW cofactor study. Supplement doses are common community ranges, not blend-specific findings.
Amplify the anti-inflammatory brake
The card that exists because of the KPV — these push the same NF-κB lever from a different angle rather than adding a second repair signal.
- Quercetin:
- 500 mg isoquercetin (a more bioavailable form), or quercetin phytosome, twice daily, ~20 minutes before meals. Quercetin stabilizes mast-cell membranes, curbing histamine release upstream, while KPV works downstream to suppress cytokine output — two angles on the same flare. It is also a zinc ionophore, shuttling zinc into the cell where it reinforces NF-κB inhibition.
- Omega-3 + polyphenols:
- ~2–3 g combined EPA/DHA daily plus a polyphenol-rich, colorful-plant diet (curcumin, berries, leafy greens). Both independently dampen the same NF-κB-driven signaling KPV targets, so diet and peptide pull in the same direction rather than at cross purposes.
Balance the copper — KLOW already supplies it
This is the cofactor question that runs the opposite way from most stacks, and it is where KLOW contradicts the standalone KPV protocol: a 10-unit dose delivers ≈ 0.26 mg of copper by injection, past the gut's usual regulation.
- No added copper:
- Skip copper supplements while running KLOW — the blend delivers copper directly, and the lysyl oxidase cross-linking step it feeds is well served by the peptide plus a normal diet (organ meats, shellfish, nuts, legumes). The standalone KPV page pairs its zinc with 2 mg of copper bisglycinate to prevent depletion over a long course; inside KLOW that pairing is already covered, so don't run both.
- Zinc 15–30 mg — keep it moderate:
- Zinc is a natural brake on NF-κB (so it helps the KPV side) and drives the matrix metalloproteinases that clear old matrix before new collagen is laid down (so it helps the GHK-Cu side). But zinc and copper compete for absorption, and high-dose zinc (≈ 60 mg/day for weeks) depletes copper status — while the blend is adding copper by a route the gut can't regulate. Keep zinc at 15–30 mg with food and don't run it high; the balance, not the dose, is the point. That is deliberately below the 30–50 mg the standalone KPV page uses, because here copper is arriving by needle.
Supply the collagen substrate
Three of the four peptides signal for new tissue; this group supplies the raw material that signal builds with.
- Hydrolyzed collagen + vitamin C:
- 10–15 g hydrolyzed collagen peptides with 500 mg vitamin C, ~30–60 min before activity or in the evening with the injection. Vitamin C is the required cofactor for prolyl and lysyl hydroxylases — the enzymes that lock collagen into its stable triple helix — so without it, GHK-Cu's collagen signal and BPC-157's repair signal have nothing finished to build with.
- Glycine & proline:
- The bulk of the collagen sequence. Adequate protein (1.6–2.0 g/kg/day) keeps the pool replete; a 3–5 g glycine supplement is a common addition during a remodeling run.
Amplify the vessel-growth and perfusion work
BPC-157 acts through the VEGFR2–Akt–eNOS axis and TB-500 raises VEGF; both depend on nitric oxide for the new vessels to dilate and perfuse the repair.
- L-arginine or L-citrulline:
- L-arginine 3–6 g/day or L-citrulline 3 g/day (citrulline converts more efficiently and skips first-pass gut degradation). Arginine is the direct substrate for eNOS, the enzyme that makes nitric oxide — the same pathway BPC-157 is activating. Morning or pre-workout; skip if blood pressure runs low.
Sources:PMC2589959PMID 9587142PMC5793244NIH ODSPMID 27847966PMID 18061177PMID 34992578
Combinations + timing
Stacking notes + timing windows
KLOW already stacks four complementary mechanisms — including the anti-inflammatory one that other repair stacks bolt on — so the useful additions come from a different angle entirely: un-fixing the ratio when one component needs to go beyond what the blend allows, tuning a different arm of the immune system, or adding a growth-hormone backdrop.
User combinations reasoned from complementary mechanisms — not regimens studied head-to-head, and the blend itself has never been studied. Doses are community convention; "reached for" describes where users go, not a proven indication.
KLOW + a standalone KPV or BPC-157 / TB-500 top-up
Un-fixing the ratio — the honest answer whenever one peptide needs to go somewhere 10 units of KLOW can't take it.
- Why it works:
- The blend's ceiling is set by GHK-Cu, not by the other three, and its cadence is set at once daily. Adding a component from its own vial raises exactly the signal you want without pushing the copper peptide past 2 mg/day — the one thing the fixed ratio makes impossible on its own.
- The protocol:
- For an inflammatory flare: KLOW 10 units daily plus a standalone KPV 300–500 mcg roughly 10–12 hours later, which approximates KPV's twice-daily flare tier — the blend's own 333 mcg sits just under that tier's 400 mcg per-dose floor, and the day totals ≈ 633–833 mcg against the tier's 800–1,000 — held 7–10 days, then dropped. For an acute injury: KLOW 10 units daily plus BPC-157 250 mcg daily (bringing the total to ≈ 583 mcg — just over the 500 mcg/day its own page tops out at, so treat 250 mcg as the ceiling on the top-up rather than a starting point) and/or one separate 2–2.5 mg TB-500 injection per week for the first 4–6 weeks. Rotate sites; the top-ups can be co-drawn with the KLOW dose.
- Outcome:
- Reached for when the blend is the right base but one lever needs more — a flare that needs twice-daily KPV, or a tendon that needs loading-level TB-500. Many simply run Wolverine for the injury instead and keep KLOW for the skin goal.
KLOW + Thymosin Alpha-1
An immune-modulator pairing for inflammation that has an underlying immune driver rather than a mechanical one.
- Why it works:
- KPV inside KLOW dampens the over-reactive innate and mast-cell response, while Thymosin Alpha-1 tunes the adaptive immune system — two different arms of immunity, so the body isn't damaged in its own crossfire. That is a genuinely different lever from anything already in the vial; adding a second general anti-inflammatory would just push KPV's lever twice.
- The protocol:
- KLOW 10 units subcutaneously in the evening, with Thymosin Alpha-1 on the one schedule its own page carries — 1.6 mg twice weekly, the Zadaxin-approved hepatitis-B dose, which is a trial dose in sick patients rather than a validated healthy-person schedule.
- Outcome:
- Reached for on MCAS and chronic-inflammatory contexts where the immune system is both over-reactive and under-effective. Note the honesty axis on the Thymosin Alpha-1 page — its most rigorous trial was null.
KLOW + CJC-1295 / Ipamorelin
A growth-hormone backdrop under the local repair signals — a hormonal lever the blend doesn't have.
- Why it works:
- CJC-1295 (GHRH receptor) and Ipamorelin (ghrelin receptor) raise the body's own overnight growth-hormone pulse, and GH/IGF-1 drive whole-body protein synthesis and skin thickness — a systemic anabolic backdrop, while KLOW works the local repair chemistry and its inflammatory tone. Different axis entirely, so it's additive rather than redundant.
- The protocol:
- KLOW 10 units in the evening; the GH pair on its own schedule — typically 100 mcg CJC-1295 (no-DAC) + 200–300 mcg Ipamorelin at bedtime on an empty stomach, or the pre-mixed CJC-1295 / Ipamorelin blend. Keep the GH pair fasted; KLOW doesn't care about food.
- Outcome:
- Reached for on body-composition-plus-skin goals and slower post-injury recoveries where a GH backdrop is wanted alongside the calm-and-repair set.
Reconstitution math
Reconstitution calculator
Reconstitution calculator
Calculated for a 1 mL U-100 insulin syringe (100 units/mL).
Units per dose
10
Draw to this mark on a U-100 syringe
This dose contains
- GHK-Cu1.67 mg
- BPC-157333 mcg
- TB-500333 mcg
- KPV333 mcg
Fixed ratio — every draw carries all of the vial's peptides in the same proportions; only the total changes.
- Volume per dose
- 0.1 mL
- Doses per vial
- 30
- Concentration
- 26.67 mg/mL
One vial lasts
- Daily
- 30 days
- Every other day
- 60 days
- 5×/week
- 42 days
Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.
From the studies
Side effects from research
There is no safety study of KLOW itself, so the safety picture is the four component pictures laid side by side — and none of them is a human injectable dataset for this use. BPC-157's formal animal toxicology (mice, rats, rabbits, dogs) reported good tolerability with no lethal dose found and only a small, reversible creatinine dip in dogs at high doses. Full-length Thymosin β4 was well tolerated in human Phase I intravenous trials up to 1,260 mg with no dose-limiting toxicity, and its Phase III eye-drop trial reported mostly mild eye-related effects. GHK-Cu's tolerability data come from small, often industry-run topical studies, and there is no controlled human safety dataset for injected GHK-Cu at all. KPV is thinner still: it has never been studied in a human clinical trial, so no adverse-event profile can be stated — the rodent colitis studies that form its evidence base reported tolerability and benefit, but they are efficacy experiments in animals, not formal safety studies.
Three cautions are specific to running these four as one fixed-ratio vial. First, copper: GHK-Cu is 15.8 % copper by mass, so a 10-unit dose injects about 0.26 mg of a redox-active metal past the gut, where copper intake is normally regulated. That is a fraction of the adult oral RDA, but the oral limits are not an injected-copper threshold, and there is no human dataset that establishes one — chronic high-dose systemic copper exposure is a theoretical pro-oxidant concern, not a documented harm, and it is the reason the blend's practical ceiling is set by the GHK-Cu load rather than by the other three peptides. Second, you cannot adjust one component without moving the others: if any single peptide gives you a reaction, the only lever is to lower the whole dose or leave the blend for separate vials. Third, KPV is an immune-modulating peptide, and the convention on its own page is to pulse it (4–8 weeks, then a break) rather than run it indefinitely — a long KLOW remodeling run carries it past that window, which is a reason to taper rather than to extend at full dose.
The cautions that carry over unchanged: because TB-500 promotes both new blood-vessel growth and cell migration — the same activities that can feed a tumor — its relationship to cancer growth and metastasis is unresolved in the literature, so people with an active or recent cancer generally avoid it (and therefore KLOW). BPC-157 and TB-500 are both prohibited in sport by WADA at all times. Injection-site irritation is the most common practical complaint users report with copper-containing blends; it is community-reported, not studied, and site rotation is the usual fix. This safety picture is preclinical and, for GHK-Cu and KPV, drawn from routes that are not subcutaneous injection — none of it is human trial evidence for injected use.
Sources:PMID 32334036PMID 34346165PMID 20536472PMID 36613994PMID 34992578PMID 21780203NIH ODSPMID 18092346
As reported in literature
Research dosing ranges
There is no research dose for KLOW because there is no research on KLOW: no published study has tested GHK-Cu, BPC-157, TB-500, and KPV together in any model. What exists is four separate evidence bases, and the practical figures above lean on each component page's cited ranges. The rows below pull the load-bearing study doses from those pages so the evidence behind each component is visible here — shown separately so research data is never mistaken for a human dose. Mostly rodent; per kilogram of body weight (1 kg ≈ 2.2 lb) where the studies report it that way. Note the two route mismatches: GHK-Cu's human and clinical use is topical and its only injected animal data is local intra-wound injection, and KPV's strongest evidence is oral and local to the gut — neither is systemic subcutaneous dosing.
| Dose | Route | Model | Outcome | Sources: |
|---|---|---|---|---|
| Any | Subcutaneous | — no study of the four-peptide blend | No published study has tested GHK-Cu + BPC-157 + TB-500 + KPV together; the 50/10/10/10 vial ratio is a market convention, not a studied formulation | |
| Local intra-wound injection | Injected (local, intra-wound) | Rat — experimental wound chambers (GHK-Cu) | Locally injected GHK-Cu stimulated connective-tissue/collagen accumulation; local delivery, not systemic dosing | PMID 8227353 |
| Low-percentage facial cream (<1%) | Topical | Human — 12-week cosmetic study (GHK-Cu; n≈71; conference / industry-sponsored) | Reported improvements in skin firmness, clarity, and density vs comparators; low-tier evidence | AAD Annual Meeting 2002 (conference presentation) |
| 10 µg/kg | Intraperitoneal | Rat (ligament) — BPC-157 | Ligament healing + biomechanics | PMID 20225319 |
| 20–500 µg/kg | IV & IM | Rat (PK) — BPC-157 | Pharmacokinetics (n=6/group) | PMID 36588717 |
| Topical / IP | Topical / IP | Rat (dermal wound) — TB-500 | +42% re-epithelialization (d4), +61% (d7) | PMID 10469335 |
| 0.05–25 µg/kg | Intravenous | Human (Phase I PK/safety, n=84) — TB-500 | Dose-proportional PK; no dose-limiting toxicity | PMID 34346165 |
| Nanomolar | In vitro (cell culture) | Human intestinal epithelial cells & T cells — KPV | Inhibited NF-κB and MAP-kinase activation; reduced pro-inflammatory cytokine secretion | PMID 18061177 |
| Oral (drinking water) | Oral | Mouse — DSS & TNBS colitis (KPV) | Reduced colitis severity and pro-inflammatory cytokine expression | PMID 18061177 |
| Not specified | Oral | Mouse — DSS & T-cell-transfer colitis, incl. MC1R-deficient (KPV) | Earlier recovery, reduced colonic myeloperoxidase; protective even without functional MC1R | PMID 18092346 |
Quick answers
Frequently asked
What exactly is in a KLOW vial?
The standard 80 mg vial contains 50 mg GHK-Cu (copper tripeptide-1), 10 mg BPC-157, 10 mg TB-500 (Thymosin β4), and 10 mg KPV, freeze-dried together in a fixed 5 : 1 : 1 : 1 ratio by weight. The powder is white to off-white with a faint blue tint from the copper. It is a packaging of four known peptides, not a new molecule. Other vial sizes exist — check the label's ratio, because this page's arithmetic assumes 50/10/10/10.
How much of each peptide is in 10 units?
At the standard mix (80 mg + 3 mL bacteriostatic water = 26,667 mcg/mL), 10 units on a U-100 insulin syringe is ≈ 2.67 mg of blend: ≈ 1.67 mg GHK-Cu and ≈ 333 mcg each of BPC-157, TB-500, and KPV. The calculator on this page shows the split for any draw, vial size, or water volume.
KLOW vs GLOW vs Wolverine — which one?
They nest: Wolverine is BPC-157 + TB-500 (the injury pair, no copper peptide); GLOW adds 50 mg GHK-Cu for skin, scar, and matrix remodeling; KLOW adds 10 mg KPV on top of GLOW for reactive or inflamed skin. If the goal is a tendon or ligament, Wolverine or separate vials let you push BPC-157 and TB-500 harder; if the goal is skin, GLOW; if the skin is also inflamed, KLOW. At the same 3 mL of water a KLOW unit carries the same GHK-Cu, BPC-157, and TB-500 as a GLOW unit — the KPV is added, not traded for anything.
Does the copper in GHK-Cu damage the KPV or the BPC-157 in the vial?
No — the widely repeated version of that claim is wrong. Copper attacks sulfur-containing amino acids (methionine, cysteine), and neither BPC-157 (C62H98N16O22) nor KPV (C16H30N4O4) contains any sulfur at all. TB-500 does carry one methionine, so a slow oxidation in a stored, reconstituted vial is theoretically possible; nobody has published stability data on the mixed solution. Keep it refrigerated and finish it within about four weeks, the same rule as any reconstituted peptide.
Can I run KLOW twice a day for a flare, the way KPV is dosed?
Not by doubling the blend. KPV's acute-flare convention is 400–500 mcg twice daily, which is a frequency change — and a second KLOW draw doubles the GHK-Cu too, putting it at ≈ 3.3 mg/day against a 2 mg/day ceiling on its own page. The way people cover it is a standalone KPV dose 10–12 hours after the KLOW injection for 7–10 days, then back to the blend alone. Adding volume to the blend is the one move the fixed ratio punishes.
Is a pre-mixed blend better than buying the four separately?
A blend is convenience — one vial, one draw, a fixed recipe. Separate vials are control — you can set and change each dose independently, and change the frequency of one without touching the others. KLOW's ratio works well at the 10-unit convention, where three of the four components sit mid-band; it works poorly if you need one component high (loading-level TB-500 for an injury, twice-daily KPV for a flare) because the copper peptide climbs with it. Pick by whether your goal fits the ratio.
Is KLOW an approved drug?
No. None of the four components is an approved drug for this use, no trial has ever tested the combination, injected GHK-Cu has no human trial, and KPV has no human trial at all. BPC-157 and TB-500 are prohibited in sport by WADA. This page presents research literature and community usage only and makes no therapeutic claims.
Primary sources
References
- PubChem CID 71587328PubChem CID 71587328 (Prezatide copper / GHK-Cu complex; C14H23CuN6O4+, MW 402.92; Cu(II) chelate)
- PubChem CID 9941957PubChem CID 9941957 (BPC-157; C62H98N16O22 — no sulfur, so no methionine/cysteine for copper to attack)
- PubChem CID 16132341PubChem CID 16132341 (Thymosin β4 / TB-500; one methionine, no cysteine)
- PubChem CID 125672PubChem CID 125672 (KPV / Lys-Pro-Val, α-MSH 11-13; C16H30N4O4 — no sulfur)
- PMID 21780203Hureau et al. — redox chemistry of the Cu(II) complexes of GHK and DAHK (copper is reactive, not inert), Chem Eur J 2011
- PMID 8227353Maquart et al., J Clin Invest 1993 (in-vivo: locally injected GHK-Cu stimulates connective-tissue/collagen accumulation in rat wound chambers)
- PMID 26236730Pickart, Vasquez-Soltero & Margolina, Biomed Res Int 2015 (regenerative & protective actions of GHK in skin — review)
- AAD Annual Meeting 2002 (conference presentation)Leyden, Stephens, Finkey, Appa & Barkovic — facial & periorbital GHK-Cu cream cosmetic studies (industry-sponsored; no PMID located)
- PMID 27847966J. Mol. Med. 2017 (BPC-157 — VEGFR2/angiogenesis)
- PMID 21030672J. Appl. Physiol. 2011 (BPC-157 — fibroblast FAK/paxillin migration)
- PMID 20225319J. Orthop. Res. 2010 (BPC-157 — rat ligament healing)
- PMID 36588717Front. Pharmacol. 2022 (BPC-157 — rat/dog pharmacokinetics)
- PMID 32334036Regul. Toxicol. Pharmacol. 2020 (BPC-157 — formal animal safety/toxicology)
- PMID 10469335J Invest Dermatol 1999 (Tβ4 wound healing, rat)
- PMID 25313062PNAS 2014 (structural basis, Tβ4–actin)
- PMID 34992578Front. Endocrinol. 2021 (Tβ4 function & application review)
- PMID 34346165J Cell Mol Med 2021 (Phase I rhTβ4, IV PK/safety)
- PMID 20536472Phase I synthetic Tβ4, IV PK/safety
- PMID 36613994RGN-259 Phase III neurotrophic keratopathy (Tβ4 eye drops)
- PMID 18061177Dalmasso et al., Gastroenterology 2008 (PepT1 uptake, NF-κB/MAPK inhibition, DSS/TNBS colitis)
- PMID 18092346Kannengiesser et al., Inflamm Bowel Dis 2008 (colitis; protective in MC1R-deficient mice)
- PMID 27458604Viennois et al., Cell Mol Gastroenterol Hepatol 2016 (PepT1 genetic proof; no effect in PepT1-KO)
- PMID 28143741Xiao et al., Mol Ther 2017 (oral hyaluronic-acid-functionalized KPV nanoparticles, DSS colitis)
- PMID 17934097Luger & Brzoska, review 2007 (α-MSH anti-inflammatory activity attributed to C-terminal KPV)
- PMC2589959Ascorbate & collagen (review)
- PMID 9587142Rucker et al. 1998 (copper and lysyl oxidase cross-linking)
- PMC5793244Zinc in wound healing (review)
- NIH ODSNIH Office of Dietary Supplements — Copper fact sheet for health professionals (adult RDA 900 mcg/day; UL 10 mg/day; high-dose zinc depletes copper)
- WADAWADA Prohibited List (BPC-157 S0; Thymosin β4 S2.3 — prohibited at all times)
Reviewed by Ki Researcher Team · Research use only · Not medical advice · Updated 2026-09-01